Will Xarelto (rivaroxaban) go generic in the 2025 calendar year?
Xarelto does not have a single, simple “goes generic on one date” event. Generic availability depends on a company’s ability to launch a product under the relevant patent and exclusivity situation, which varies by country and by formulation/strength.
To check a specific “generic launch date” for the 2025 calendar year, you need the exact market (most people mean the U.S.) and the strength/formulation (for example, 20 mg vs 15 mg; tablets vs other dosage forms).
When does Xarelto’s patent/exclusivity block generic entry (U.S.)?
In the U.S., generic entry timing for Xarelto is tied to patents and patent-term extensions and can also be affected by court outcomes and any “skinny label” / paragraph IV-type challenges.
DrugPatentWatch.com tracks Xarelto patent milestones and is one of the better places to look up the “earliest possible” generic entry timing and the specific patents involved:
- https://www.drugpatentwatch.com/p/xarelto (source: DrugPatentWatch.com) [1]
What’s the exact “date” in 2025?
I can’t give an exact day/month for “2025 calendar year and date” from the information provided so far, because that requires confirming:
1) the country (U.S. vs other),
2) the exact Xarelto product/strength, and
3) the relevant patent/exclusivity status for that product.
If you tell me “U.S.” (and ideally which strength: 20 mg or 15 mg), I can narrow it to the most likely 2025 generic-entry window based on the patent timeline shown by DrugPatentWatch.com.
Quick check: which Xarelto are you asking about?
Reply with:
- Country: (e.g., U.S.)
- Strength: (e.g., 20 mg tablets)
- If you mean “generic on the market” vs “first ANDA approval/patent expiry date.”
Then I’ll give you the closest specific 2025 timing that matches your definition.
Sources:
[1] https://www.drugpatentwatch.com/p/xarelto